Quick navigation menu :

  1. Go to main section's menu
  2. Go to Search tool
  3. Go to Help menu
  4. Go to modules
  5. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worlwide |
     
  2. Global Business Websites |
     
  3. Contact Us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce Increase  
 
 

Thrombosis

Contact

Sanofi Bangladesh Limited

6/2/A Segun Bagicha
Dhaka 1000
Bangladesh

Tel. : +880 96 78 000 777
Fax : +880 2 955 0009

Content :

Thrombosis

Thrombosis

Venous Thromboembolism (VTE), which is the obstruction of a vein by a blood clot, is the third most common cardiovascular disease in the western world, occurring in about 0.1% of people every year.
Thrombosis affects both the arterial (Atherothrombosis) and venous (Venous Thromboembolism) systems.

 

Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE), which is the obstruction of a vein by a blood clot, is the third most common cardiovascular disease in the western world, occurring in about 0.1% of people every year. The most common manifestation of VTE is deep venous thrombosis (DVT) which occurs when a clot forms in the deep veins of the lower limbs. This is a common condition in elderly ill patients who are bedridden, post-surgical patients who are immobilised for a period of time as well as in patients who undergo major surgical and orthopaedic procedures. It can also occur in patients who have a genetic condition predisposing to abnormal clotting of blood. The most serious consequence of a DVT is pulmonary embolism (PE). This occurs when the clot (or pieces of) dislodges and moves to the lungs and causes a blockage to the blood vessels of the lungs. PEs are serious and carry a significant fatality rate. Sanofi produces the leading low molecular weight heparin that has been proven in numerous clinical trials to prevent and treat of VTE.

Atherothrombosis (AT)

Atherothrombosis (AT) occurs when a blood clot forms on fatty deposits in the wall of a blood vessel. It is a dangerous condition because if the clot grows and completely blocks an affected artery, blood stops flowing and the tissue downstream to the blockage is at risk, sometimes with life-threatening consequences. If AT occurs in the arteries of the heart, a blockage leads to Acute Coronary Syndromes (ACS) or heart attacks. Similarly, if it occurs in the arteries supplying the brain, ischemic strokes (IS) occur. Peripheral arterial disease (PAD) occurs when AT affects the arteries of the lower limbs. AT is increasingly common due to our modern lifestyles. With advancing medical knowledge and therapies, patients who are at high risk of developing atherothrombosis can be identified and managed accordingly. Sanofi produces the leading anti-platelet agent that has also been proven by numerous clinical trials to treat and prevent recurrent AT events.

Updated January 23, 2007